Top

Published in:

01-03-2011 | Original Article

Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study

Authors: L.-A. Fraser, G. Ioannidis, J. D. Adachi, L. Pickard, S. M. Kaiser, J. Prior, J. P. Brown, D. A. Hanley, W. P. Olszynski, T. Anastassiades, S. Jamal, R. Josse, D. Goltzman, A. Papaioannou, the CaMos Research Group

Published in: Osteoporosis International | Issue 3/2011

Abstract

Summary

Canadian women over 50 years old were studied over a 10-year period to see if those who sustained a fracture (caused by minimal trauma) were receiving the recommended osteoporosis therapy. We found that approximately half of these women were not being treated, indicating a significant care gap in osteoporosis treatment.

Introduction

Prevalent fragility fracture strongly predicts future fracture. Previous studies have indicated that women with fragility fractures are not receiving the indicated treatment. We aimed to describe post fracture care in Canadian women using a large, population-based prospective cohort that began in 1995–1997.

Methods

We followed 5,566 women over 50 years of age from across Canada over a period of 10 years in the Canadian Multicentre Osteoporosis Study. Information on medication use and incident clinical fragility fractures was obtained during a yearly questionnaire or interview and fractures were confirmed by radiographic/medical reports.

Results

Over the 10-year study period, 42–56% of women with yearly incident clinical fragility fractures were not treated with an osteoporosis medication. During year 1 of the study, 22% of the women who had experienced a fragility fracture were on treatment with a bisphosphonate and 26% were on hormone therapy (HT). We were not able to differentiate HT use for menopause symptoms vs osteoporosis. Use of bisphosphonate therapy increased over time; odds ratio (OR) for use at year 10 compared to use at year 1 was 3.65 (95% confidence interval (CI) 1.83–7.26). In contrast, HT use declined, with an OR of 0.07 (95%CI 0.02–0.24) at year 10 compared to year 1 of the study.

Conclusion

In a large population-based cohort study, we found a therapeutic care gap in women with osteoporosis and fragility fractures. Although bisphosphonate therapy usage improved over time, a substantial gap remains.

Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMed

Ross PD, Davis JW, Epstein RS, Wasnich RD (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919–923PubMed

Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34PubMed

Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, Brown JP (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10:120–123CrossRefPubMed

The National Osteoporosis Foundation (NOF) Clinician's Guide to prevention and treatment of osteoporosis 2008. National Osteoporosis Foundation, Washington, DC

AACE Osteoporosis Task Force (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564

Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, Brown JP et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703–714CrossRefPubMed

Kado KM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR (1999) Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporostic Fractures Research Group. Arch Intern Med 159:1215–1220CrossRefPubMed

Keen RW (2003) Burden of osteoporosis and fractures. Curr Osteoporos Rep 1:66–70CrossRefPubMed

10.

Ioannidis G, Papaioannou A, Hopman WM et al (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181:265–271PubMed

11.

Ensrud KE, Thompson DE, Cauley JA et al (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241–249PubMed

12.

Bessette L, Ste-Marie LG, Jean S et al (2008) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 19:79–86CrossRefPubMed

13.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed

14.

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516CrossRefPubMed

15.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2002) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD001155

16.

Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, Shea B, Tugwell P, Wells G (2001) Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev 4:CD003376PubMed

17.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G (2003) Risedronate for the prevention and treatment of postmenopausal osteoporosis. 4:CD004523

18.

Hajcsar EE, Hawker G, Bogoch ER (2000) Investigation and treatment of osteoporosis in patients with fragility fracture. Can Med Assoc J 163:819–822

19.

Papaioannou A, Giangregorio L, Kvern B et al (2004) The osteoporosis care gap in Canada. BMC Musculoskelet Disord 5:11CrossRefPubMed

20.

Giangregorio L, Papaioanou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility Fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305CrossRefPubMed

21.

Papaioannou A, Kennedy CC, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 19:581–587CrossRefPubMed

22.

Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS (1999) The Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376–387CrossRef

23.

Kingwell E, Prior JC, Ratner PA, Kennedy SM (2010) Direct-to-participant feedback and awareness of bone mineral density testing results in a population-based sample of mid-aged Canadians. Osteoporos Int 21:307–319CrossRefPubMed

24.

Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linearmodels. Biometrika 73:13–22CrossRef

25.

Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M (2003) Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 85:2294–2302PubMed

26.

Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. A gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172CrossRefPubMed

27.

Metge CJ, Leslie WD, Manness LJ, Yogendran M, Yuen CK, Kvern B, the Maximizing Osteoporosis Management in Manitoba Steering Committee (2008) Postfracture care for older women. Gaps between optimal care and actual care. Can Fam Physician 54:1270–1276PubMed

28.

Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Jt Surg 84A:1342–1348

29.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

30.

Klotzbuecher CM, Ross PD, Landsmen PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739CrossRefPubMed

31.

Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. N Engl J Med 332:767–773CrossRefPubMed

32.

Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE (1999) Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 25:613–619CrossRefPubMed

33.

Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos M, Kreiger N, Olszynski WP, Josse RG, Goltzman D (2009) Vertebral fracture status and the World Health Organization (WHO) risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24:495–502CrossRefPubMed

34.

Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433–493CrossRefPubMed

35.

Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135CrossRefPubMed

36.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed

37.

Cranney A, Jamal SA, Tsang TF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177:575–580PubMed

38.

The North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRef

39.

Sanders KM, Pasco JA, Ugoni AM, Nicholson GC, Seeman E, Martin TJ, Skoric B, Panahi S, Kotowicz MA (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res 13:1337–1342CrossRefPubMed

40.

Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMed

41.

Osteoporosis Canada (2007). Provincial access to etidronate, alendronate, risedronate, calcitonin, raloxifene and teriparatide. Retrieved November 22, 2009 from http://www.osteoporosis.ca/index.php/ci_id/5521/la_id/1.htm

42.

Poliquin S, Joseph L, Gray-Donald K (2009) Calcium and vitamin D intakes in an adult Canadian population. Can J Diet Pract Res 70(1):21–27CrossRefPubMed

43.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMed

44.

Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMed

Title: Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study
Authors: L.-A. Fraser
G. Ioannidis
J. D. Adachi
L. Pickard
S. M. Kaiser
J. Prior
J. P. Brown
D. A. Hanley
W. P. Olszynski
T. Anastassiades
S. Jamal
R. Josse
D. Goltzman
A. Papaioannou
the CaMos Research Group
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1359-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2011

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos

Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement

Polymorphisms in the 5′ flank of COL1A1 gene and osteoporosis: meta-analysis of published studies

Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study

Guidance for the adjustment of FRAX according to the dose of glucocorticoids